drugset
drugset / Trial / NCT03332355

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

NCT03332355 ↗

Phase 1 Terminated 18 enrolled Vanquish Oncology, Inc. University of Illinois at Chicago · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objectives of this study are to determine the maximal tolerated dose (MTD) of PAC-1 in combination with temozolomide in patients with high grade glioma: glioblastoma multiforme (GBM) or anaplastic astrocytoma after progression following standard first line therapy (Component 2), by evaluation of toxicity and tolerability.

Timeline

Start
2017-10-01
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PAC-1 Small molecule 450 mg —
Subject Temozolomide Small molecule 150 mg/m2 Oral

Indications

anaplastic astrocytoma glioblastoma